FDA Actions Against IPCA LABS LTD

FDA action counts

Enforcement history

On 2026-09-22, Argus HQ recorded an FDA approval for IPCA LABS LTD, rated "info" severity in Argus HQ's classification: IPCA LABS LTD — ANDA approval: AMLODIPINE BESYLATE (unspecified). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. IPCA LABS LTD has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

Does Argus HQ track new FDA actions for IPCA LABS LTD automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to IPCA LABS LTD is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for IPCA LABS LTD?

1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for IPCA LABS LTD?

September 22, 2026. Argus HQ ingests new FDA enforcement records daily.

Is this FDA enforcement data for IPCA LABS LTD official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Related enforcement actions

• IPCA LABS LTD — ANDA approval: AMLODIPINE BESYLATE (unspecified) →

Compare with

• IPCA LABS LTD vs Philips North America
• IPCA LABS LTD vs Medline Industries, LP
• IPCA LABS LTD vs Boston Scientific Corporation
• IPCA LABS LTD vs Baxter Healthcare Corporation
• IPCA LABS LTD vs PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.